22,324 Shares in Vaxcyte, Inc. $PCVX Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,324 shares of the company’s stock, valued at approximately $1,270,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. First Light Asset Management LLC increased its holdings in Vaxcyte by 143.4% in the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock valued at $20,064,000 after acquiring an additional 203,373 shares during the last quarter. Bank of America Corp DE lifted its stake in Vaxcyte by 73.4% in the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after purchasing an additional 515,209 shares in the last quarter. Candriam S.C.A. bought a new position in shares of Vaxcyte during the 1st quarter valued at about $18,306,000. Seven Fleet Capital Management LP boosted its holdings in shares of Vaxcyte by 406.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock valued at $7,464,000 after purchasing an additional 103,085 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in shares of Vaxcyte during the 2nd quarter valued at about $1,906,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.92, for a total value of $182,760.00. Following the completion of the transaction, the chief accounting officer owned 27,860 shares of the company’s stock, valued at approximately $1,697,231.20. This trade represents a 9.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 2,250 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.90, for a total transaction of $137,025.00. Following the completion of the transaction, the executive vice president directly owned 145,435 shares of the company’s stock, valued at approximately $8,856,991.50. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 50,692 shares of company stock worth $4,032,875. Insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX opened at $63.89 on Monday. The stock has a market capitalization of $9.51 billion, a PE ratio of -7.93 and a beta of 1.31. The company’s fifty day moving average is $61.71 and its 200 day moving average is $57.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.56 and a current ratio of 4.56. Vaxcyte, Inc. has a fifty-two week low of $40.14 and a fifty-two week high of $90.75.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same quarter in the prior year, the business posted ($1.56) EPS. Sell-side analysts expect that Vaxcyte, Inc. will post -7.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PCVX. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Needham & Company LLC boosted their target price on Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $120.00 price target on shares of Vaxcyte in a research note on Monday, October 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.50.

About Vaxcyte

Vaxcyte, Inc is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response.

The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.

Founded as SutroVax, the company adopted the Vaxcyte name in 2020.